Key facts
- Hirotsu Bio Science’s last known valuation is $500.0M (Jan 2025).
- It has raised $125.5M; the latest was Secondary Transaction - Private ($60.0M) in Feb 2026.
- Notable investors include SBI Investment, Mitsui Sumitomo Insurance Co., Shinkin Capital, Aioi Nissay Dowa Insurance, As One (Japan) — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Hirotsu Bio Science
- ·The full record, as it builds
Funding rounds
No funding rounds for Hirotsu Bio Science are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hirotsu Bio Science
Developer of a cancer detection technology designed to identify small amounts of cancerous odors in urine with high accuracy. The company offers a revolutionary, highly accurate, and comprehensive screening test that utilizes the sense of smell of living organisms, enabling individuals worldwide to access early and reliable detection of cancer for improved health outcomes.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2016
- Employees
- 100
- Website
- hbio.jp/
- Ownership
- Privately Held (backing)
Hirotsu Bio Science doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hirotsu Bio Science shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hirotsu Bio Science in its N-PORT filings yet. We sweep new filings monthly.